Atara Biotherapeutics experiences a plunge in share prices after the Food and Drug Administration holds up approval of a drug ...

Atara Biotherapeutics (ATRA) plans to cut around 50% of its workforce, just a little over a week after the FDA declined to ...

Atara Biotherapeutics’ layoffs could leave the biotech with around 80 employees. The cuts follow news that the FDA rejected ...

H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating on January 21.Invest with ...

This decision comes in the wake of the Food and Drug Administration's (FDA) Complete Response Letter (CRL) regarding Atara's EBVALLO application and the subsequent halt of several clinical trials.

“We are disappointed by the delay and are willing to work with Atara on appropriate next steps to bring Ebvallo to U.S. patients that suffer from this deadly rare disease (the drug treats ...

This decision comes in the wake of the Food and Drug Administration's (FDA) Complete Response Letter (CRL) regarding Atara's EBVALLO application and the subsequent halt of several clinical trials.

NEW YORK CITY, NY / ACCESS Newswire / January 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Atara Biotherapeutics (NASDAQ:ATRA) has announced plans to cut around 50% of its workforce, just a little over a week after it said the FDA had declined to approve its immunotherapy Ebvallo.